Zacks Investment Research downgraded shares of DexCom Inc. (NASDAQ:DXCM) from a hold rating to a strong sell rating in a research note released on Tuesday.

According to Zacks, “DexCom Inc.’s margins would continue to be come under pressure in the coming quarters owing to high product development costs and rising expenditures on research & development along with marketing. Specifically, the company is expected to lose a few margins on transmitter sales in spite of the cost reduction initiatives (which are expected to be effective only by the second half of 2017). Additionally, cutthroat competition in the market for blood glucose monitoring devices is a major headwind. Entry of additional products in this market would also make it challenging for DexCom to protect or grow its market share. In fact DexCom might face supply constraints in the near-term with an increasing demand for its offerings. This is because the company relies highly on third parties for an assured steady supply of inputs.”

Other analysts also recently issued reports about the company. BTIG Research reiterated a buy rating and set a $92.00 target price on shares of DexCom in a research report on Tuesday, July 19th. JPMorgan Chase & Co. reiterated a buy rating and set a $100.00 target price on shares of DexCom in a research report on Wednesday, August 3rd. Jefferies Group reiterated a buy rating and set a $98.00 target price on shares of DexCom in a research report on Wednesday, August 3rd. Benchmark Co. decreased their target price on DexCom from $106.00 to $86.00 and set a buy rating for the company in a research report on Wednesday, August 3rd. Finally, Deutsche Bank AG lifted their target price on DexCom from $90.00 to $98.00 and gave the stock a buy rating in a research report on Friday, July 15th. One analyst has rated the stock with a sell rating, four have issued a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the stock. DexCom has an average rating of Buy and a consensus target price of $95.08.

Shares of DexCom (NASDAQ:DXCM) traded up 1.95% during trading on Tuesday, reaching $83.53. 466,376 shares of the company were exchanged. The firm’s market capitalization is $7.01 billion. DexCom has a 1-year low of $47.92 and a 1-year high of $96.38. The firm’s 50 day moving average is $91.52 and its 200 day moving average is $77.66.

DexCom (NASDAQ:DXCM) last released its earnings results on Tuesday, August 2nd. The medical device company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.12) by $0.12. DexCom had a negative return on equity of 19.68% and a negative net margin of 16.42%. The business had revenue of $137.30 million for the quarter, compared to the consensus estimate of $132.48 million. During the same quarter last year, the business posted ($0.05) earnings per share. The firm’s revenue for the quarter was up 47.3% compared to the same quarter last year. On average, equities analysts anticipate that DexCom will post ($0.57) EPS for the current fiscal year.

In related news, insider Jorge A. Valdes sold 32,000 shares of the business’s stock in a transaction that occurred on Monday, July 11th. The stock was sold at an average price of $79.36, for a total transaction of $2,539,520.00. Following the completion of the sale, the insider now directly owns 123,667 shares in the company, valued at $9,814,213.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Andrew K. Balo sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 13th. The stock was sold at an average price of $80.12, for a total value of $400,600.00. Following the sale, the executive vice president now owns 134,979 shares of the company’s stock, valued at $10,814,517.48. The disclosure for this sale can be found here. Corporate insiders own 2.80% of the company’s stock.

Hedge funds have recently modified their holdings of the company. Loomis Sayles & Co. L P boosted its stake in shares of DexCom by 0.4% in the first quarter. Loomis Sayles & Co. L P now owns 25,898 shares of the medical device company’s stock valued at $1,759,000 after buying an additional 94 shares during the last quarter. Public Employees Retirement Association of Colorado boosted its stake in shares of DexCom by 0.5% in the second quarter. Public Employees Retirement Association of Colorado now owns 19,466 shares of the medical device company’s stock valued at $1,544,000 after buying an additional 94 shares during the last quarter. Hsbc Holdings PLC boosted its stake in shares of DexCom by 2.6% in the second quarter. Hsbc Holdings PLC now owns 3,944 shares of the medical device company’s stock valued at $313,000 after buying an additional 100 shares during the last quarter. Eqis Capital Management Inc. boosted its stake in shares of DexCom by 1.7% in the second quarter. Eqis Capital Management Inc. now owns 7,246 shares of the medical device company’s stock valued at $575,000 after buying an additional 119 shares during the last quarter. Finally, Metropolitan Life Insurance Co. NY boosted its stake in shares of DexCom by 4.0% in the second quarter. Metropolitan Life Insurance Co. NY now owns 6,183 shares of the medical device company’s stock valued at $490,000 after buying an additional 239 shares during the last quarter. Hedge funds and other institutional investors own 99.37% of the company’s stock.

DexCom Company Profile

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers for the treatment of people with and without diabetes. Its products include SEVEN PLUS, DexCom G4, DexCom G4 PLATINUM, DexCom Share System and DexCom G5 Mobile.

5 Day Chart for NASDAQ:DXCM

Receive News & Stock Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related stocks with our FREE daily email newsletter.